Buchanan, R. J., & Huang, C. (2012). Caregiver perceptions of accomplishment from assisting people with multiple sclerosis. Disability and rehabilitation, 34, 53–61.

Article  PubMed  Google Scholar 

Palmer, A. J., van der Mei, I., Taylor, B. V., Philip, M. C., Steve, S., & Hasnat, A. (2019). Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458519831213

Article  PubMed  Google Scholar 

McKay, K. A., Kwan, V., Duggan, T., & Tremlett, H. (2015). Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: A systematic review. BioMed Research International. https://doi.org/10.1155/2015/817238

Article  PubMed  PubMed Central  Google Scholar 

Lublin, F. D., & Reingold, S. C. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology, 46, 907–911.

Article  CAS  PubMed  Google Scholar 

Zhang, Y., Taylor, B., Simpson, S., Jr., Blizzard, L., & Mei, I. (2019). Patient-reported outcomes are worse for progressive-onset multiple sclerosis than relapse-onset multiple sclerosis, particularly early in the disease process. European Journal of Neurology, 26, 155–161.

Article  CAS  PubMed  Google Scholar 

Caseby, S. C. L., Woodhouse, F. A., Montgomery, S. M., Kroes, M. A., & Duddy, M. E. (2022). Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey. Health Science Reports, 5, e474.

Article  PubMed  PubMed Central  Google Scholar 

Inusah, S., Sormani, M. P., Cofield, S. S., Aban, I. B., Musani, S. K., Srinivasasainagendra, V., & Cutter, G. R. (2010). Assessing changes in relapse rates in multiple sclerosis. Multiple Sclerosis Journal, 16, 1414–1421.

Article  PubMed  Google Scholar 

Goudarzi, M. H., Eadie, M. J., & Hollingworth, S. A. (2021). Disease modifying therapies for relapsing-remitting multiple sclerosis: Use and costs in Australia (1996–2019). Multiple Sclerosis and Related Disorders, 50, 102835.

Article  PubMed  Google Scholar 

Salter, A., Lancia, S., Cutter, G., Marrie, R. A., Mendoza, J. P., Lewin, J. B., & Fox Mellen, R. J. (2021). A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod. Therapeutic Advances in Neurological Disorders, 14, 17562864211021176.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cree, B. A., Magnusson, B., Rouyrre, N., Fox, R. J., Giovannoni, G., Vermersch, P., Bar-Or, A., Gold, R., Meier, D. P., Karlsson, G., Tomic, D., Wolf, C., Dahlke, F., & Kappos, L. (2021). Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 27, 1564–1576.

Article  PubMed  Google Scholar 

Lorscheider J, Buzzard K, Jokubaitis V, et al. Defining secondary progressive multiple sclerosis. Brain 2016; 139: 2395-2405.

Kobelt, G., Berg, J., Lindgren, P., et al. (2006). Costs and quality of life of multiple sclerosis in Switzerland. The European Journal of health economics, 7, 86–95.

Article  Google Scholar 

Hawton, A., & Green, C. (2016). Health utilities for multiple sclerosis. Value in health, 19, 460–468.

Article  PubMed  Google Scholar 

Orme, M., Kerrigan, J., Tyas, D., et al. (2007). The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value in health, 10, 54–60.

Article  PubMed  Google Scholar 

Mäurer, M., Comi, G., Freedman, M. S., et al. (2016). Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life–A post hoc analysis of the TEMSO and TOWER studies. Multiple Sclerosis and Related Disorders, 7, 33–40.

Article  PubMed  Google Scholar 

Drummond, M. F., Sculpher, M. J., Claxton, K., et al. (2015). Methods for the economic evaluation of health care programmes. Oxford University Press.

Google Scholar 

Herdman, M., Gudex, C., Lloyd, A., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of life research, 20, 1727–1736.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Norman, R., Cronin, P., & Viney, R. (2013). A pilot discrete choice experiment to explore preferences for EQ-5D-5L health states. Applied Health Economics and Health Policy, 11, 287–298.

Article  PubMed  Google Scholar 

Richardson, J., Sinha, K., Iezzi, A., et al. (2014). Modelling utility weights for the Assessment of Quality of Life (AQoL)-8D. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 2014(23), 2395–2404. https://doi.org/10.1007/s11136-014-0686-8

Article  Google Scholar 

Chen, G., & Olsen, J. A. (2020). Filling the psycho-social gap in the EQ-5D: The empirical support for four bolt-on dimensions. Quality of Life Research, 29, 3119–3129.

Article  PubMed  PubMed Central  Google Scholar 

Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 2002(21), 271–292.

Article  Google Scholar 

Brazier, J. E., Mulhern, B. J., Bjorner, J. B., et al. (2020). Developing a New Version of the SF-6D health state classification system from the SF-36v2: SF-6Dv2. Medical Care, 58, 557–565.

Article  PubMed  Google Scholar 

Richardson, J., Khan, M. A., Iezzi, A., et al. (2015). Comparing and explaining differences in the magnitude, content, and sensitivity of utilities predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D multiattribute utility instruments. Medical Decision Making, 35, 276–291.

Article  PubMed  Google Scholar 

Kennedy-Martin, M., Slaap, B., Herdman, M., et al. (2020). Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. The European Journal of Health Economics, 21, 1245–1257.

Article  PubMed  PubMed Central  Google Scholar 

Hernandez, L., O’Donnell, M., & Postma, M. (2021). Predictors of health utility in relapsing-remitting and secondary-progressive multiple Sclerosis: Implications for future economic models of disease-modifying therapies. PharmacoEconomics, 39, 243–256.

Article  PubMed  Google Scholar 

Henriksson, F., Fredrikson, S., Masterman, T., et al. (2001). Costs, quality of life and disease severity in multiple sclerosis: A cross-sectional study in Sweden. European journal of neurology, 8, 27–35.

Article  CAS  PubMed  Google Scholar 

Kobelt, G., Berg, J., Lindgren, P., et al. (2006). Costs and quality of life in multiple sclerosis in Europe: Method of assessment and analysis. The European Journal of Health Economics, 7, 5–13.

Article  Google Scholar 

Kobelt, G. (2006). Costs and quality of life for patients with multiple sclerosis in Belgium. The European Journal of Health Economics, 7, 24–33.

Article  Google Scholar 

Kobelt, G., Berg, J., Atherly, D., et al. (2006). Costs and quality of life in multiple sclerosis a cross-sectional study in the United States. Neurology, 66, 1696–1702.

Article  PubMed  Google Scholar 

Kobelt, G., Berg, J., & Lindgren, P. (2006). Costs and quality of life in multiple sclerosis in The Netherlands. The European Journal of Health Economics, 7, 55–64.

Article  Google Scholar 

Kobelt, G., Berg, J., Lindgren, P., et al. (2006). Costs and quality of life of multiple sclerosis in Italy. The European Journal of Health Economics, 7, 45–54.

Article  Google Scholar 

Kobelt, G., Berg, J., Lindgren, P., et al. (2006). Costs and quality of life of multiple sclerosis in Germany. The European journal of health economics, 7, 34–44.

Article  Google Scholar 

Kobelt, G., Berg, J., Lindgren, P., et al. (2006). Costs and quality of life of multiple sclerosis in Spain. The European Journal of Health Economics, 7, 65–74.

Article  Google Scholar 

Kobelt, G., Berg, J., Lindgren, P., et al. (2006). Costs and quality of life of multiple sclerosis in the United Kingdom. The European Journal of Health Economics, 7, 96–104.

Article  Google Scholar 

Kobelt, G., Berg, J., Lindgren, P., et al. (2006). Costs and quality of life of multiple sclerosis in Austria. The European Journal of Health Economics, 7, 14–23.

Article  Google Scholar 

Grima, D., Torrance, G., Francis, G., et al. (2000). Cost and health related quality of life consequences of multiple sclerosis. Multiple Sclerosis Journal, 6, 91–98.

Article  CAS  PubMed  Google Scholar 

Prosser, L. A., Kuntz, K. M., Bar-Or, A., et al. (2003). Patient and community preferences for treatments and health states in multiple sclerosis. Multiple Sclerosis Journal, 9, 311–319.

Article  PubMed  Google Scholar 

Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol 2012; 19: e11–25. 2012/01/17.

Oleen-Burkey M, Castelli-Haley J, Lage MJ, et al. Burden of a multiple sclerosis relapse: the patient's perspective. Patient 2012; 5: 57–69. 2012/01/06. DOI: https://doi.org/10.2165/11592160-000000000-00000.

Ruutiainen, J., Viita, A.-M., Hahl, J., et al. (2016). Burden of illness in multiple sclerosis (DEFENSE) study: The costs and quality-of-life of Finnish patients with multiple sclerosis. Journal of Medical Economics, 19, 21–33. https://doi.org/10.3111/13696998.2015.1086362

Article  PubMed  Google Scholar 

Kobelt G, Teich V, Cavalcanti M, et al. Burden and cost of multiple sclerosis in Brazil. PLoS One 2019; 14: e0208837. 2019/01/24. DOI: https://doi.org/10.1371/journal.pone.0208837.

Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 33, 1444–1444.

Article  CAS  PubMed  Google Scholar 

Julie A Campbell* and Hasnat Ahmad* GC, Ingrid van der Mei, Bruce Taylor, Suzi Claflin, Glen J Henson, Steve Simpson-Yap, Laura Laslett, Kirsty Hawkes, Carol Hurst, Hilary Waugh and Andrew J Palmer. Validation of the EQ-5D-5L and psychosocial bolt-ons in a large cohort of people living with multiple sclerosis in Australia. Quality of life research 2022; Under Review.

Taylor BV, Palmer A, Simpson S, et al. Assessing possible selection bias in a national voluntary MS longitudinal study in Australia. Multiple Sclerosis Journal 2013: 1352458513481511.

Ahmad, H. (2021). Health Economic Consequences of Multiple Sclerosis in Australia. University of Tasmania.